OVERVIEW

  • Understand the risk factors that contribute to the elevated risk for thrombotic cardiovascular events pre- and post-myocardial infarction in patients across the coronary artery disease spectrum
  • Differentiate oral P2Y12 inhibitors with respect to their clinical pharmacology and examine the select differences between oral antiplatelet therapies
  • Describe the role of BRILINTA in reducing the risk of cardiovascular events in patients with acute coronary syndrome, history of myocardial infarction, and high-risk coronary artery disease without prior myocardial infarction

This content is developed exclusively by or on behalf of the industry sponsor through a third party and is not reviewed by Pri-Med. The content and opinions expressed are those of the sponsor or presenters and may not reflect the views of Pri-Med.


Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.